HIGHER MORTALITY OF DIABETIC PATIENTS IN HEART FAILURE: ROLE OF DIGOXIN
European Journal of Molecular & Clinical Medicine,
2021, Volume 8, Issue 3, Pages 633-642
AbstractBackground: Digitalis glycosides have been in clinical use in the treatment of congestive heart failure for more than 200 years. Heart failure has a great physical, social and economic impact on patient’s life. Diabetes adds to adverse effects of heart failure.
Aim &objective: Study was aimed to assess the role of digoxin in patients with heart failure with and without type 2 diabetes and to, access the role of digoxin to reverses NYHA class of patients and number of hospitalization in a year . The outcome of patients of heart failure with and without type 2 Diabetes mellitus was also observed.
Methodology: This prospective study has undertaken 70 patients visiting to department of medicine/cardiology at a tertiary health care centre. Patients with heart failure were studied for one year. Data collected with pre-tested questionnaire. Clinical history (specially h/o diabetes meillitus), clinical examination were examined. Patients are treated with drugs like digoxin, beta blockers, ACE inhibiters etc depending upon etiology and symptoms of the patients. Which is followed for upto 1 year and finally the outcomes was measured in terms of reversal of NYHA class, and mortality.
Results & discussion: Mean age of the patients was 62.31±3.1 years. Out of 70 patients 36 were male and 34 were female. Diabetic patients were having significantly higher mortality than non-diabetic patients with heart failure. (p<0.05). Digoxin therapy reverses the NYHA class but it is statistically not significant. (p<0.05). In diabetic patients receiving digoxin number of hospitalizations (9/12) were more than that of non-diabetic patients (8/26).
Conclusion: Diabetic patients have more adverse effects in heart failure than in non-diabetic patients.
KEYWORDS : Cardiovascular diseases, Heart failure, Digitalis, Digoxin, Diabetes.
- Article View: 304
- PDF Download: 345